Background: Long-term opioid prescribing for musculoskeletal pain is controver-
| INTRODUCTION
Internationally, the use of prescribed opioid analgesics has increased substantially (Bedson et al., 2016; Farias et al., 2017; Foy et al., 2016; Manchikanti, Fellows, Ailinani, & Pamapti, 2010; Zin, Chen, & Knaggs, 2014) . Most opioid prescribing is for noncancer pain and painful chronic musculoskeletal conditions account for two-thirds of long-term opioid prescribing (Ray, Chung, Murray, Hall, & Stein, 2016) . In UK primary care, 20% of adults consult with a musculoskeletal problem annually (Jordan et al., 2010) . There was a 41% increase in patients with musculoskeletal pain prescribed opioids long-term (≥90 days) in the United Kingdom between 2002 and 2011. The proportion of these patients who were prescribed stronger, long-acting opioids rose from 4% to 23% between 2002 and 2013 (Bedson et al., 2016) .
Long-term opioid prescribing for musculoskeletal pain is controversial due to uncertainty regarding effectiveness and safety. Evidence for the long-term effectiveness of opioids from randomized placebo-controlled trials is lacking (Chou et al., 2015) . A recent trial with 12-month follow-up found opioids were no more effective than non-opioid analgesics for chronic back pain and osteoarthritis (Krebs et al., 2017) . However, limited evidence from open-label studies (Hauser, Bernardy, & Maier, 2015) , combined with clinical experience and expert consensus suggests some patients may benefit from opioids in a multifaceted pain management strategy (O'Brien et al., 2017) .
A Cochrane review reported significantly increased risks of a range of adverse events (including constipation, nausea, pruritus, dizziness and drowsiness) with medium and longterm opioid use in chronic noncancer pain (Els et al., 2017) . Additionally, there was a paucity of follow-up data beyond 13 weeks and a lack of important adverse events reporting, including overdose and addiction, and on their association with opioid dose. US observational studies report associations between long-term opioid use and serious adverse events including bone fractures and overdose Saunders et al., 2010) . Solomon investigated adverse events in opioid users in the USA between 1996 and 2005 and found that some including fractures and all-cause mortality were potentially related to the opioid agent (Solomon et al., 2010) . A US study reported increased risk of all-cause mortality during the first 180 days of therapy in patients prescribed opioids versus anticonvulsants and low-dose tricyclic antidepressants for chronic pain (Ray et al., 2016) . However, since these findings are restricted to subgroups of patients within the US healthcare system, their generalizability is uncertain.
We aimed to address the limitations of existing evidence by investigating a broad spectrum of adverse events potentially associated with prescribed long-term opioids in a large UK primary care electronic heath record database and to determine how any increased risks varied by opioid dose prescribed.
One potential limitation of using observational data to investigate the risks of long-term opioids is confounding by indication. To reduce the risk of confounding, we have set our study within a population of patients with painful musculoskeletal conditions and included only patients who have ever been prescribed opioids long-term. Our assumption is that these were all patients for whom their GP had considered that opioids were a potentially appropriate analgesic and not contraindicated for long-term use. We compared adverse events during episodes of long-term prescribing to adverse events during time periods where these patients were not prescribed long-term opioids, adjusting for important covariates and including "control" outcomes.
| METHODS

| Database
This was a cohort study performed in the Clinical Practice Research Datalink (CPRD), an anonymized database of routinely recorded information from UK general practices. The population included in CPRD is representative of the UK population on age, gender and ethnicity, and validation studies generally show high levels of positive predictive values of diagnosis codes (Herrett et al., 2015; Herrett, Thomas, & Schoonen, 2010) . CPRD comprises information from over 20 million patients registered in more than 650 primary care practices spread throughout the United Kingdom (Tate et al., 2014; Williams, Staa, Puri, & Eaton, 2012) . In the United Kingdom, the vast majority of the population are registered with a general practice, and it is here that 90% of all National Health Service (NHS) contacts occur (Gregory, 2009) . Practices included in our analysis (n = 350, all from England) were required to have linked Office for National Statistics (ONS, for mortality information), Hospital Episode Statistics (HES), and Index of Multiple Deprivation (IMD, neighbourhood deprivation) data (Department for Communities & Local Government, 2010) . Practices with and without linkage have been shown to be similar in respect of demographic data, years of follow-up, and prescribing (Gallagher, Puri, & Staa, 2011) .
| Cohort identification
Cohort participants were those aged 18 years and over, starting a new long-term opioid episode at the time of a recorded noninflammatory, potentially painful musculoskeletal condition between 2002 and 2012, as described previously (Bedson et al., 2016) . Patients were included if a visit for a musculoskeletal condition occurred within a period starting 14 days before the initial opioid prescription, and up to | BEDSON Et al. 90 days following it. This timeframe was chosen as it generated a temporal association between the musculoskeletal problem and the prescription, such that any painful musculoskeletal problem occurring within that time frame would potentially be affected by the opioid.
Musculoskeletal conditions were chosen because they are a common reason for patients consulting in primary care, are associated with chronic pain in the majority of cases (Woolf et al., 2004) and represent the commonest causes of chronic noncancer pain (Breivik, Collett, Ventafridda, Cohen, & Gallacher, 2006) . Regular opioid use is more common in this group (Hudson, Edlund, Steffick, Tripathi, & Sullivan, 2008) and chronic noncancer pain accounts for the majority of the escalation in strong opioid prescribing (Zin et al., 2014) .
Musculoskeletal conditions were identified using previously defined Read codes taken from Chapters 1 (History and symptoms), N (Musculoskeletal), R (Symptoms) and S (Injury) (Jordan et al., 2010) . Read codes are a hierarchical coded thesaurus of clinical terms used for recording morbidity in UK primary care (NHS Digital, 2018) . The codes used in the current study are available at www. keele.ac.uk/mrr/morbiditydefinitions/. Each participant was also required to have at least 12 months of records in the CPRD database before the initial opioid prescription and have no record of cancer diagnosis prior to the initial opioid prescription and up to 6 months after the initial prescription.
| Long-term opioid use
Opioids were defined as analgesics used to relieve moderate to severe pain from sections 4.7.1 and 4.7.2 of the British National Formulary (BNF) (BNF, 2017) . The start of an episode of opioid prescribing was defined as the date an opioid prescription was issued for a patient who had not received an opioid prescription within the previous 6 months. Long-term opioid prescribing was defined as the issue of at least two further opioid prescriptions within the 90-day period following the date the new opioid prescription was issued (i.e., at least three opioid prescriptions in total within 90 days). An episode of long-term opioid prescribing ended if a period of 6 months elapsed without an opioid prescription. This definition is based on a classification of longterm opioid use that has been employed in previous studies Von Korff et al., 2008) . The end date of a long-term opioid episode was defined as the date 28 days following the issue of the last opioid prescription, in keeping with local health authority guidance setting a maximum of 28-day supply of medication per prescription (O'Dowd, 2011 ). An individual patient may therefore have had multiple episodes of long-term opioid prescribing over the study period.
| Average daily dose
Daily morphine equivalent dose (MED) is an accepted method of assigning a standard value for the dose of the many different opioids based on tables of their relative potency compared to morphine. The MED for each opioid medication was obtained by using a conversion factor for morphine equivalence shown in Table 1 , and detailed morphine equivalence sources are available at https://www.keele.ac.uk/mrr/ morbiditydefinitions/. The MED for a single prescription was calculated by multiplying the quantity of medication prescribed by the conversion factor. With respect to longacting opioid patches (e.g., buprenorphine and fentanyl), the total MED for the patch was calculated by firstly determining the 24-hr MED using the appropriate conversion factor to determine the amount released per hour multiplying by 24 and then by the number of days the patch was prescribed for use (e.g., 4 or 7 days). Total morphine equivalent dose (total MED) in a long-term opioid episode was calculated by adding the MEDs for each prescription dispensed during the episode. Average daily morphine equivalent dose (average daily MED) prescribed was the total MED for a long-term opioid episode divided by episode duration in days. In those participants, where an outcome of interest occurred within a long-term opioid episode, average MED was calculated only for the period before that outcome occurred, in order to minimize the influence from a potential prescribing change due to an outcome event.
Average daily dose for each long-term opioid episode was grouped into three categories (<20 mg MED; ≥20 and <50 mg MED; ≥50 mg MED) adapted from a previous study .
| Follow-up
Cohort participants were followed up from the date 90 days after the initial opioid prescription in their first long-term opioid episode until the study end date (10 January 2012) or the date the patient no longer contributed data (due to leaving the practice, the practice leaving CPRD or patient death), whichever occurred earlier.
| Outcome measures
As primary outcomes, we examined two adverse events with some previous evidence of an association with long-term opioid use in studies within selected healthcare populations in the United States, namely, major trauma and intentional overdose (opioid or other; Dunn et al., 2010) .
We defined major trauma as a bone fracture, joint dislocation, ligament or tendon rupture, or head trauma (including subdural haemorrhage). Read code examples of opioid overdose included "self-poisoning with an opioid" and nonopioid overdose "self-poisoning with a hypnotic." It was not possible to determine whether the codes used related to fatal or nonfatal overdoses.
Secondary outcomes were attempted suicide/self-harm (excluding overdose), incident addiction (opioids), incident addiction (other type), falls, accidental poisoning, newly diagnosed gastrointestinal pathology (inflammatory or erosive, e.g., "peptic ulcer"), gastrointestinal bleeding (gastric and nongastric bleeding) and new diagnosis of iron deficiency anaemia (potentially occurring because of gastrointestinal bleeding). Accidental poisoning was coded per se, since all Read codes used to identify this type of outcome specifically state "accidental," for example, accidental poisoning by other tranquillisers (Code T83yz). All other self-poisonings or overdoses were then classified as intentional, since CPRD GPs are trained to use appropriate codes for the problem being documented, and where self-poisoning was "accidental," this would be labelled as such, leaving other codes inherently as intentional. This list includes adverse events where limited evidence of an association with long-term opioid use currently exists (Els et al., 2017) , and where recognized side effects of opioids such as delayed gastrointestinal motility, confusion, dependence, drowsiness, dysphoria, postural hypotension, vertigo and visual disturbances make an association feasible (BNF, 2017) . Additionally, abdominal pain is a reported adverse effect from using the opioid codeine phosphate (BNF, 2017) , and reports of anaemia have been recorded by the US FDA Adverse Events Recording System in users of opioids such as codeine (eHealthMe, 2017) . We therefore included gastrointestinal pathologies which can cause both abdominal pain and anaemia to investigate any association with opioid use.
We also included two dermatological control outcomes, new diagnosis of eczema or psoriasis, that theoretically should have no relationship with long-term prescribed opioids. These act as "negative controls" to identify possible sources of bias (e.g., due to unmeasured confounding; Arnold, Ercumen, Benjamin-Chung, & Colford, 2016; Lipsitch, Tchetgen, & Cohen, 2010) . Our hypothesis was that failure to identify an association of long-term opioid prescribing with these control outcomes would increase confidence that any associations found for the primary and secondary outcomes are less likely to be due to possible sources of bias.
Outcomes of interest were the first recording of these adverse events within the follow-up period. Outcomes were analysed separately so an individual patient could have multiple different adverse events. All potential adverse events were identified through Read Codes in CPRD and Read Codes mapped to ICD-10 codes in the linked HES dataset, or where relevant through the linked ONS dataset for events ending in mortality. All relevant adverse event codes (available from https://www.keele.ac.uk/mrr/morbiditydefinitions/) appropriate for the analysis were identified through a consensus exercise by two academic primary care physicians (JB and RAH), experienced in identifying database codes. An incident event or new diagnosis was defined as a record made during the follow-up period with no such record during the 15 months prior to start of follow-up (365 days prior to initial opioid prescription to 90 days after).
| Covariates
Possible confounding covariates were identified. Prior occurrence of adverse events, except for those where the outcome was defined as an incident event or new diagnosis, was identified in the 15-month period prior to start of follow-up.
Smoking and alcohol information were classified as ever, never or missing based on data prior to start of follow-up date. The missing category was included to maximize numbers in analysis. BMI value used was the record at the closest date
before the start of follow-up and was grouped into <25 kg/ m 2 , ≥25 kg/m 2 (overweight) or missing.
Geographical region was grouped as London, South of England, Midlands and East of England, and North of England. Deprivation level, based on the Index of Multiple Deprivation 2010 [Department for Communities and Local Government], was categorized based on quintile score (one least, five most deprived). The deprivation measure is an ecological indicator based on area of residence, covering seven aspects of neighbourhood deprivation including income, employment, health deprivation and disability, education skills and training, barriers to housing and services, crime, and living environment.
Depression has been linked to use of opioids in studies from the United States (Scherrer, Salas, Copeland et al., 2015; Scherrer, Salas, Lustman, Burge, & Schneider, 2015; Scherrer et al., 2013) . We identified prior recorded depression in the 15 months prior to start of follow-up.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of gastrointestinal adverse events (Lanza, Chan, & Quigley, 2009 ); therefore, co-prescribing of a NSAID was identified using prescription data for the 4 months prior to follow-up start (to ensure any potential clinical NSAID-related adverse events that might manifest themselves for up to 90 days after finishing a prescription of NSAID, usually issued for 28 days, could be taken into account).
The total number of prescriptions for drugs recorded under different BNF sections in the 15-month period prior to start of follow-up was used as a surrogate measure of the number of co-morbid conditions at baseline (Perkins et al., 2004) .
| Statistical analysis
The rate of each of the adverse events per 10,000 personyears at risk was determined during follow-up, stratified by whether or not they occurred during an episode of long-term opioid prescribing and by average daily dose during a longterm opioid episode.
Patients were followed up from 90 days after their initial opioid prescription in their first long-term episode. For subsequent new opioid prescribing episodes, the first 90 days was used to determine long-term opioid prescribing status according to our definition of ≥3 prescriptions in the first 90 days, and this 90-day period was therefore excluded from the analysis of adverse events. Patients with an adverse event in that 90 days were censored at time of initial opioid prescription for that episode. Proportional hazards modelling was used to compare the risk of adverse events occurring during episodes of long-term opioid prescribing with the risk of adverse events occurring during episodes when long-term opioids were not being prescribed. Long-term opioid prescribing and average daily dose were treated as time-dependent exposures. Patients were categorized as either currently being in a long-term opioid episode or not currently being prescribed opioids. In those within a long-term episode, patients were further categorized based on average daily dose (<20 mg MED; ≥20 and <50 mg MED; ≥50 mg MED). Separate models were performed for each adverse event and for each of the two exposures (long-term episode status and average daily dose).
Cox regression was used to produce both unadjusted and adjusted hazard ratios (HRs) for each outcome separately, estimating the excess risk of each adverse event associated with long-term opioid prescribing. The validity of the proportional hazards assumption was tested using Schoenfeld residuals and deemed adequate for the exposure variables of long-term opioid prescribing and average daily dose. Age at baseline, gender, year of start of follow-up, ever smoking, ever alcohol drinking, overweight (BMI ≥25 kg/m 2 ), geographical region, deprivation level, prior recorded depression, co-prescribing of NSAID and total number of co-morbid conditions were included as baseline covariates in the final model. For the outcomes of major trauma, falls, intentional overdose (opioids and non-opioids separately) and accidental poisoning, baseline previous events were also included in the final model. For the outcomes of incident gastrointestinal conditions and bleeding, iron deficiency anaemia, addiction (opioids and non-opioids separately), eczema and psoriasis, patients with a previous event in their records were excluded from the analysis. We further stratified analysis by gender. A sensitivity analysis excluded patients with missing data on covariates. Analysis used Stata14.1.
| RESULTS
A total of 98,140 patients were prescribed long-term opioids during the study period. The median age (at start of followup) was 61 years, and 41% were males. Baseline characteristics are given in Table 2 . Patients were followed for a median of 3.4 years (IQR 1.6, 5.8).
A total of 106,818 long-term opioid episodes were identified during the study period. The median length of long-term opioid episodes was 237 days (IQR 103, 658) . This may be an underestimate as it includes the 27.4% of episodes that were not completed by the end of follow-up. Within longterm opioid episodes, the median average daily dose of opioid prescribed to patients was 12.3 mg MED (IQR 7.1, 20.3 mg MED; Table 3 ).
Increased risks for major trauma and overdose (of both non-opioids and opioids) were found during episodes of long-term opioid prescribing, compared to periods when long-term opioids were not prescribed. Furthermore, higher risks were associated with a higher average daily MED. For example, risk of major trauma increased from 285/10,000 person-years at risk in periods when long-term opioids were not prescribed to 369/10,000 (average daily dose of <20 mg MED), 382/10,000 (20-50 mg MED) and 424/10,000 (≥50 mg MED) in periods of long-term opioid prescribing. Adjusted hazard ratios for the increase in risk were 1.09 (95% CI; 1.04, 1.14 compared to not being in an episode of long-term use; <20 mg MED), 1.24 (95% CI; Table 4 ). Dose-response relationships (i.e., increased risk in periods of stronger long-term opioid prescribing) were also identified for the secondary outcomes of falls, iron deficiency anaemia, gastrointestinal events, addiction and accidental poisoning. The number of attempted suicide/self-harm events was small, with no statistically significant relationship with long-term opioids observed (Table 5) .
Prescriptions of long-term opioids were not associated with increased risks of eczema or psoriasis, regardless of average daily dose (Table 6) .
Adjusted risks of adverse events were similar between females and males (Supporting Information Tables S1-S4).
Sensitivity analysis using complete case analysis gave very similar results.
| DISCUSSION AND CONCLUSIONS
This study of nearly 100,000 patients in UK primary care has shown a dose-dependent increase in the risk of overdose and major trauma when patients were prescribed long-term opioids for chronic musculoskeletal pain. Intentional opioid overdose was nearly four times more likely in patients prescribed long-term opioids at the highest doses (≥50 mg) compared to periods when they were not receiving long-term opioids. Similarly, patients prescribed the highest doses also had a 71% higher risk of intentional non-opioid overdose and a 34% higher major trauma risk, compared to time periods when they were not prescribed long-term opioids. Dose-dependent increases in the risk of addiction, falls, accidental poisoning, incident gastrointestinal pathology, gastrointestinal bleeding and iron deficiency anaemia with current longterm opioid compared to periods of no long-term use were also identified.
The median average daily dose of prescribed opioids during long-term opioid episodes was 12.3 mg (IQR 7.1, 20.3 mg MED) . This is consistent with an earlier dosage study of opioid prescribing (Von Korff et al., 2008) and another indicating that 95% of initially prescribed opioids in long-term episodes were for low-dose short-acting noncontrolled opioids (Bedson et al., 2016) .
Our study findings are consistent with smaller long-term opioid use observational studies in the United States which demonstrated dose-dependent increases in the risk of bone fractures , opioid overdose and addiction (Edlund et al., 2014) . Our finding of a dose-dependent increased risk of falls seems consistent with the increased risk of major trauma identified. In contrast, one large prospective longitudinal study found no significant association of opioids with falls or fractures in an all-male cohort (Krebs et al., 2016) . However, this discrepancy may relate to the absence of data on opioid dose or duration, thereby potentially reducing the study's power to detect a dose-dependent association if most events occur at higher doses. Adverse events in opioids might be related to the preparation. One systematic review found that transdermal buprenorphine was less likely to be related to adverse effects than other opioids (Richardson, Bedson, Chen, Lacey, & Dunn, 2018) , and Solomon found that fractures were less likely in those who were prescribed tramadol compared to hydrocodone (Solomon et al., 2010) . However, since our study considers MED as the main variable, we are unable to examine this phenomenon, and therefore, potentially some outcomes may be related more to the type of opioid than the MED. A higher risk of erosive gastrointestinal pathology, gastrointestinal bleeding and iron deficiency anaemia has not previously been identified in relation to long-term opioids. Opioids may impair oesophageal motility and delay gastric emptying, potentially worsening gastro-oesophageal reflux (Ratuapli et al., 2015) ; however, its clinical relevance is uncertain. Opioids are used as an alternative to NSAIDs for patients at risk of peptic ulcers and we cannot rule out residual confounding. Long-term use of paracetamol (>13 weeks) has been associated with gastrointestinal blood loss (Doherty et al., 2011) , and a systematic review reported higher rates of upper gastrointestinal bleeding in paracetamol users (Roberts et al., 2016) . Paracetamol is frequently used in combination with opioids. Potentially, long-term opioid prescribing increases the likelihood of regular, long-term paracetamol use and that this is the risk factor associated with increased risk of gastrointestinal events, rather than the use of opioids per se. Although the analysis adjusted for prescribed NSAIDs, it did not adjust for paracetamol which may be purchased over the counter. Further exploration of this phenomenon is needed.
T A B L E 3 Average daily dose of prescribed opioids during the long-term opioid episodes
Percentiles (%)
A Cochrane review highlighted the lack of reporting on several important adverse events, such as addiction and overdose, and recommended longer follow-up to detect adverse events which this study has now examined. (Els et al., 2017) .
Reproductive and sexual dysfunction occurs in male longterm opioid users. No such association has been identified in females (Daniell, 2002; Katz & Mazer, 2009; Smith & Elliott, 2012) . Therefore, other gender-related differences in adverse events might exist. No studies have examined this area (Els et al., 2017) , and we did not identify any differences in the rates of adverse events between males and females either. Patients moved from long-term opioid use to periods of no use. This would be consistent with previous work examining the trajectories of pain which people experience. For example, in back pain, one of the commonest causes of chronic noncancer pain, pain trajectories are very variable and depend to some extent on the original presentation. Back pain sufferers can be grouped according to those with persistent severe pain, fluctuating pain, persistent mild pain and occasional pain. However, all groups vary around their mean pain trajectory (Dunn, Jordan, & Croft, 2006; Tamcan et al., 2010) which would be consistent with our findings of patients moving from periods of long-term opioid use to no use. Key strengths of this study relate to the use of CPRD, allowing analysis of a large cohort of primary care patients linked to secondary care and mortality data. All prescribing is recorded electronically in UK primary care at the point of medication issue, and there is an automatic recording of repeat opioid prescriptions. The likelihood of missing opioid prescribing data in CPRD is therefore low. Another factor facilitating the collection of outcome data and which makes our results more generalizable is the fact that primary care physicians in CPRD practices were historically requested to ensure recording of a diagnostic code for any new problem or when a new treatment is given (Lawson, Sherman, & Hollowell, 1998) . CPRD data are not limited to particular healthcare populations, for example, it is not based on medical insurance schemes as many US healthcare databases are, thereby making the results more generalizable. Additionally, this population was restricted to patients with painful musculoskeletal conditions who had all been prescribed long-term opioids. This reduces the likelihood of cofounding by indication.
T A B L E 6 Risks of eczema and psoriasis in musculoskeletal patients newly prescribed long-term opioids
Adverse events
Number of events
We adjusted for previous occurrence of the adverse events, except for outcomes defined as incident events (where patients with a previous event were excluded), and for potential confounders. Depression and overdose during the past year are strong predictors of overdose and suicide in patients taking long-term opioids (Oliva et al., 2017) . By adjusting for depression and previous overdose, we have controlled for important confounders in relation to our primary outcome of overdose and increased confidence in the study findings. However, we were unable to adjust for a previous history of substance misuse which may influence some outcomes.
We also included "control" outcomes (Arnold et al., 2016; Lipsitch et al., 2010 ) which hypothetically should not be associated with long-term opioid prescribing to detect potential bias. The absence of any dose-dependent increased risk of either control outcome (incident eczema or psoriasis) further increases our confidence in the study findings.
Our study was observational, and therefore, the results should be viewed as associations, and not necessarily causal. Our study population is restricted to patients with painful musculoskeletal conditions, and whilst this reflects the majority of patients with chronic pain, it is possible the findings may not be generalizable to those prescribed long-term opioids for nonmusculoskeletal chronic pain. However, despite chronic musculoskeletal pain representing a broad range of heterogenous conditions, in the light of recent research, (Artus, Campbell, Mallen, Dunn, & Windt, 2017; Green et al., 2018) which has demonstrated strong evidence that prognosis and prognostic factors are similar across multiple pain sites, we have assumed that the relationship of long-term opioid use with adverse events is consistent across musculoskeletal conditions, but future research should assess this further.
Our study uses opioid prescribing data from a healthcare database and cannot account for patients not taking the prescribed medication as directed. In addition, we were unable to adjust for the use of over-the-counter analgesics. Long-term opioid use for musculoskeletal conditions is highly likely to be by prescription and therefore captured within the CPRD data, given that low-dose codeine (8-12 mg maximum pack size of 32 tablets for short-term use) is the only opioid available over the counter in the United Kingdom (Medicines & Healthcare Products Regulatory Agency, 2009). However, it is possible that over-the-counter paracetamol or NSAID use may be implicated in the finding of higher risk of erosive gastrointestinal events. Additionally, though our definition of long-term opioid use is dependent on the use of three consecutive prescriptions for opioids within 90 days, we cannot be certain that patients used them consistently in that period and that every prescription was intended to last more or less than a 4-week period. Though GPs are advised to use at least 2-4 weeks of an opioid before changing or stopping (NICE, 2017) , and that at least 28 days of medication should be given (O'Dowd, 2011) , this might lead to some patients being erroneously classed as long-term users, though within the framework that GPs work, the vast majority are likely to have been classified correctly. Ultimately, however, the issue of a prescription for an opioid does not necessarily mean a patient has taken the medication. Accordingly, we cannot be certain whether a patient has used their prescribed opioids or not, though the fact that repeat prescriptions for opioids are issued in each longterm case would suggest that patients are likely to be using them. Although we adjusted for prescribed NSAID use, we did not adjust for any other prescribed medications used for chronic pain or other medications that might have impacted mental health such as antidepressants or benzodiazepines. However, we did adjust for total number of prescribed medications as a surrogate marker for co-morbidity, but no specific co-morbidities other than depression were investigated such as substance misuse or osteoporosis which may impact overdose and bone fractures. Polypharmacy and the use of other medications for pain will be reflected to some extent by that. However, we are unable to account for the specific effects of other potentially sedating medications on adverse event outcomes.
We did not include adverse events occurring during the first 90 days of opioid prescribing as outcomes due to the likelihood of these being related to patients being opioid naïve. This study aimed to look at adverse events associated with long-term opioid use, and events after 90 days are more likely to be specifically associated with long-term use. However, events within 90 days were either adjusted for, or for incident outcomes, patients with such events were excluded.
This study has shown dose-dependent associations between prescribed long-term opioids and increased risks of a range of serious adverse events. Whilst in absolute terms the increased number of events appears to be relatively small, this must be viewed in the context of both the seriousness of the events and the long-term efficacy of opioids for chronic pain. Whilst some patients may benefit from moderate doses of opioids for chronic pain, many do not (Moore, Derry, Eccleston, & Kalso, 2013) . However, they may continue to be prescribed opioids because of a perceived lack of other treatment options (Moore et al., 2013; Stannard, 2013) . It seems self-evident that patients should not be exposed to increased risk of harm, when this is not balanced by therapeutic benefit (Faculty of Pain Medicine, 2017; Stannard, 2013) . Our findings reinforce the message that doctors need to be vigilant when prescribing opioids for chronic pain, and to give due consideration to the dose prescribed and the appropriateness of continuing opioids long-term. These clinical decisions must be made on an individual patient basis, taking into account any benefits observed in terms of pain relief, the impact on functioning, side effects and the potential risks of long-term use. Opioid prescribing should be reviewed before long-term use becomes established, and periodically, thereafter to assess ongoing effectiveness. Unfortunately, the challenges facing UK Primary Care, including rising GP workload, present a major barrier to this becoming routine practice (Primary Care Workforce Commission, 2015) . Further research is needed to develop and test strategies and interventions to reduce inappropriate opioid prescribing. Given that most long-term opioid prescribing occurs in primary care, it is recommended that future research focuses on the role of multidisciplinary primary care teams, including clinical pharmacists, in reviewing patients prescribed long-term opioids.
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